Literature DB >> 10352242

Inhibition of B cell receptor-mediated apoptosis by IFN.

L Su1, M David.   

Abstract

IFNs are a family of cytokines that are involved in the regulation of immune and inflammatory responses. Clinical use of IFN-alpha/beta encompasses treatment for a variety of diseases; however, prolonged exposure to IFN-alpha/beta results in elevated levels of autoreactive Abs. In this study, we investigated the potential of IFNs to modulate apoptotic signals in B cells. We demonstrate that IFN-alpha or IFN-beta inhibit Ag receptor-mediated apoptosis in a dose-dependent manner. Inhibition of phosphatidylinositol 3' (PI3)-kinase did not abolish the effect of IFN, indicating that the antiapoptotic mechanism is PI3-kinase- and protein kinase B/Akt-independent. Instead, IFN-alpha and IFN-beta, but not IFN-gamma, significantly increase the levels of the survival protein Bcl-2, and to a lesser extent, Bcl-xL expression. Thus, IFN-alpha/beta-mediated inhibition of B cell Ag receptor-triggered apoptosis may offer a model for the process that leads to the escape of self-reactive B cells from negative selection and consequently results in autoantibody production.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10352242

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  The role of IL-6 in inhibition of lymphocyte apoptosis by mesenchymal stem cells.

Authors:  Guangwu Xu; Yingyu Zhang; Liying Zhang; Guangwen Ren; Yufang Shi
Journal:  Biochem Biophys Res Commun       Date:  2007-07-20       Impact factor: 3.575

2.  Production of borreliacidal antibody to outer surface protein A in vitro and modulation by interleukin-4.

Authors:  E L Munson; B K Du Chateau; D A Jobe; S D Lovrich; S M Callister; R F Schell
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

Review 3.  Systemic lupus erythematosus and increased risk to develop B cell malignancies: role of the p200-family proteins.

Authors:  Sudhakar Veeranki; Divaker Choubey
Journal:  Immunol Lett       Date:  2010-06-26       Impact factor: 3.685

4.  All-trans-retinoic acid and polyriboinosinic : polyribocytidylic acid in combination potentiate specific antibody production and cell-mediated immunity.

Authors:  K L DeCicco; J D Youngdahl; A C Ross
Journal:  Immunology       Date:  2001-11       Impact factor: 7.397

5.  Interferon-α induces unabated production of short-lived plasma cells in pre-autoimmune lupus-prone (NZB×NZW)F1 mice but not in BALB/c mice.

Authors:  Alexis Mathian; Mike Gallegos; Virginia Pascual; Jacques Banchereau; Sophie Koutouzov
Journal:  Eur J Immunol       Date:  2011-02-11       Impact factor: 5.532

6.  Acute endotoxemia prolongs the survival of rat lung neutrophils in response to 12-O-tetradecanoyl-phorbol 13-acetate.

Authors:  Vasanthi R Sunil; Agnieszka J Connor; Natasha Lavnikova; Carol R Gardner; Jeffrey D Laskin; Debra L Laskin
Journal:  J Cell Physiol       Date:  2002-03       Impact factor: 6.384

7.  Adhesion to fibronectin via alpha4 integrin (CD49d) protects B cells from apoptosis induced by serum deprivation but not via IgM or Fas/Apo-1 receptors.

Authors:  M Garcia-Gila; E M Lopez-Martin; A Garcia-Pardo
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

8.  Major differences in the responses of primary human leukocyte subsets to IFN-beta.

Authors:  Anette H H van Boxel-Dezaire; Joana A Zula; Yaomin Xu; Richard M Ransohoff; James W Jacobberger; George R Stark
Journal:  J Immunol       Date:  2010-10-18       Impact factor: 5.422

9.  Gamma interferon inhibits production of Anti-OspA borreliacidal antibody in vitro.

Authors:  Erik L Munson; Brian K Du Chateau; Jani R Jensen; Steven M Callister; David J DeCoster; Ronald F Schell
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

10.  Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients' individual gene expression in peripheral blood.

Authors:  Michael Hecker; Christiane Hartmann; Ole Kandulski; Brigitte Katrin Paap; Dirk Koczan; Hans-Juergen Thiesen; Uwe Klaus Zettl
Journal:  Mol Neurobiol       Date:  2013-05-01       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.